List of specific drug pages

Bendamustine

Bortezomib

Bosutinib

Gefitinib

Nilotinib

Ofatumumab

Paclitaxel

Pazopanib

Salinomycin

Antibiotics

Hormone Suppressant

Taxanes

Retinoids

Mustards

Antibiotics

Inhibitor Drugs

Anthracycline Drugs

Antifolates

Platinums

Naming of Chemo Drugs

Other Drugs

Arsenic Trioxide

Brand/Trade Names: Trisenox

Formula: As2O3

Mechanism:

Class:

Administration: Oral

Notes:  First approved by the FDA in 2000.  Used in treatment of leukemia.

Asparaginase

Brand/Trade Names: Elspar, Kidrolase

Formula: C1377H2208N382O442S17

Mechanism:

Class: Enzyme

Administration: Intravenous

Notes: Breaks down amino acid asparagine in bloodstream and thereby deprives leukemia cells of supplies of this nutrient.  Also called L-asoaaginase.  Approved by the FDA in 2011.  Used in treatment of acute lymphocytic leukemia.

Eribulin

Brand/Trade Names: Halaven

Formula: C40H59NO11

Mechanism: Mitotic Inhibitor

Class:

Administration: Intravenous

Notes: Approved by the FDA in 2010.  Used for treatment of breast cancer.

Calaspargase pegol-mknl

Brand/Trade Names: Asparlas

Formula:

Mechanism: Protein conjugate

Class: Enzyme

Administration: Intravenous

Notes:  Approved by the FDA in 2018.  Used in treatment of acute lymphoblastic leukemia.

Pegaspargase

Brand/Trade Names: Oncaspar

Formula: C1377H2208N382O442S17

Mechanism:

Class: Enzyme

Administration: Intramuscular or intravenous

Notes: Also called PEG-L-asparaginase.  Approved by the FDA in 1994.  Used in treatment of acute lymphoblastic leukemia.

Pegfilgrastim

Brand/Trade Names: Neulasta

Formula: C845H1343N223O243S9

Mechanism:

Class: colony-stimulating factor

Administration: Intramuscular or intravenous

Notes:  Approved by the FDA in 2015.  Not an anti-cancer drug. Given to help patient cope with loss of white blood cells.

Tagraxofusp-erzs

Brand/Trade Names: Elzonris

Formula:

Mechanism: Conjugate

Class:

Administration: Intravenous

Notes: Interleukin 3 (IL-3) fused to diphtheria toxin.  Approved by the FDA in 2018.